Adverse impact of cannabis on human health

M Chandy, M Nishiga, TT Wei… - Annual review of …, 2024 - annualreviews.org
Cannabis, the most commonly used recreational drug, is illicit in many areas of the world.
With increasing decriminalization and legalization, cannabis use is increasing in the United …

[HTML][HTML] Cannabinoids: Emerging sleep modulator

ZXB Low, XR Lee, T Soga, BH Goh, D Alex… - Biomedicine & …, 2023 - Elsevier
Sleep is an essential biological phase of our daily life cycle and is necessary for maintaining
homeostasis, alertness, metabolism, cognition, and other key functions across the animal …

Assessment of medical cannabis and health-related quality of life

TR Arkell, LA Downey, AC Hayley, S Roth - JAMA network open, 2023 - jamanetwork.com
Importance The use of cannabis as a medicine is becoming increasingly prevalent. Given
the diverse range of conditions being treated with medical cannabis, as well as the vast …

Adverse events of cannabidiol use in patients with epilepsy: a systematic review and meta-analysis

A Fazlollahi, M Zahmatyar, M ZareDini… - JAMA Network …, 2023 - jamanetwork.com
Importance Epilepsy is one of the most common neurologic disorders globally. Cannabidiol
(CBD) has been approved for the treatment of epilepsy, but its use has been associated with …

[HTML][HTML] Glaucoma: Novel antifibrotic therapeutics for the trabecular meshwork

M Qin, C Yu-Wai-Man - European Journal of Pharmacology, 2023 - Elsevier
Glaucoma is a chronic and progressive neurodegenerative disease characterized by the
loss of retinal ganglion cells and visual field defects, currently affecting around 1% of the …

Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies

RS Duncan, SM Riordan, MC Gernon… - Neural Regeneration …, 2024 - journals.lww.com
Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a
variety of effects in the human body. They have been studied in cellular and animal models …

Review of the treatments for central neuropathic pain

BL Sheldon, ZT Olmsted, S Sabourin, E Heydari… - Brain Sciences, 2022 - mdpi.com
Central neuropathic pain (CNP) affects millions worldwide, with an estimated prevalence of
around 10% globally. Although there are a wide variety of treatment options available, due …

Cannabinoids for substance use disorder treatment: What does the current evidence say?

JAB Fernandes, R Filev, TM Fidalgo - Cannabis and Cannabinoid …, 2023 - liebertpub.com
Background: The prevalence of Substance Use Disorder (SUD) is increasing along with the
need to develop approaches to reduce the harm associated with substance use, including …

Systematic review and meta-analysis seem to indicate that cannabinoids for chronic primary pain treatment have limited benefit

R Giossi, F Carrara, M Padroni, MC Bilancio… - Pain and Therapy, 2022 - Springer
Abstract Introduction The IASP ICD-11 chronic primary pain (CPP) definition includes 19
different painful conditions. In recent years, interest in the potential role of cannabinoids in …

Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19—A Scoping Review

C Scott, S Hall, J Zhou, C Lehmann - Journal of Clinical Medicine, 2023 - mdpi.com
Coronavirus disease-19 (COVID-19) is a highly contagious illness caused by the SARS-CoV-
2 virus. The clinical presentation of COVID-19 is variable, often including symptoms such as …